石四药集团(02005)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

02005 石四药集团

未开盘 09-02 16:08:07

2.730

+0.000

0.00%

最高2.745	最低2.690	成交量473.20万
今开2.720	昨收2.730	日振幅2.01%
总市值78.92亿	流通市值78.92亿	总股本28.91亿
成交额1,286万	换手率0.16%	流通股本28.91亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"02005","market":"HK","secType":"STK","nameCN":"石四药集团","latestPrice":2.73,"timestamp":1788336487003,"preClose":2.73,"halted":0,"volume":4732000,"delay":0,"changeRate":0,"floatShares":2891000000,"shares":2891000000,"eps":0.1605,"marketStatus":"未开盘","change":0,"latestTime":"09-02 16:08:07","open":2.72,"high":2.745,"low":2.69,"amount":12858570,"amplitude":0.020147,"askPrice":2.73,"askSize":76000,"bidPrice":2.705,"bidSize":28000,"shortable":3,"etf":0,"ttmEps":0.174609,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1788399000000},"marketStatusCode":0,"adr":0,"listingDate":1135008000000,"exchange":"SEHK","adjPreClose":2.73,"dividendRate":0.029304,"openAndCloseTimeList":[[1788312600000,1788321600000],[1788325200000,1788336000000]],"volumeRatio":0.647188463968449,"lotSize":2000,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/02005","defaultTab":"news","newsList":[{"id":"1122330324","title":"石四药集团（02005）盐酸地尔硫䓬片通过一致性评价 获批为国内第三家","url":"https://stock-news.laohu8.com/highlight/detail?id=1122330324","media":"公告速递","labels":["productRelease","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1122330324?lang=zh_cn&edition=full","pubTime":"2026-09-02 17:06","pubTimestamp":1788339985,"startTime":"0","endTime":"0","summary":"石四药集团有限公司（02005）9月2日公告称，其盐酸地尔硫䓬片（30mg）获得中国国家药品监督管理局批准，通过仿制药质量和疗效一致性评价，为国内第三家获批企业。盐酸地爾硫䓬片主要用于治疗心绞痛及轻至中度原发性高血压。\n此前，集团已取得注射用盐酸地爾硫䓬的药品生产注册批件。本次片剂一致性评价获批后，集团产品可覆盖院内急救注射及院外患者口服续贯治疗，形成针对重症监护（ICU）、心内科及急诊等场景的心脑血管产品组合。\n公告称，此次自愿披露旨在使股东及潜在投资者及时了解公司最新业务进展。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"a3893e2538b44a4c9453f52433cb6ed2","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02005"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664972948","title":"石四药集团(02005.HK)：盐酸地尔硫䓬片(30mg)已取得国家药监局批准通过仿制药质量和疗效一致性评价","url":"https://stock-news.laohu8.com/highlight/detail?id=2664972948","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2664972948?lang=zh_cn&edition=full","pubTime":"2026-09-02 17:04","pubTimestamp":1788339867,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1191","02005","LU2460026573.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1115763793","title":"石四药集团（02005）限制性股份奖励计划再购入120万股","url":"https://stock-news.laohu8.com/highlight/detail?id=1115763793","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1115763793?lang=zh_cn&edition=full","pubTime":"2026-09-02 17:01","pubTimestamp":1788339674,"startTime":"0","endTime":"0","summary":"石四药集团有限公司（02005）9月2日发布自愿公告称，计划受托人于公开市场购入合计1,200,000股公司股份，均价约2.7187港元/股，总对价约326.24万港元（不含费用），占目前已发行股份总数的约0.041%。\n本次交易完成后，受托人持股总量增至15,380,000股，占已发行股份总数约0.521%。\n上述股份将按2018年12月27日采纳的限制性股份奖励计划的条款，以信托方式持有，未来可按董事局酌情授予符合条件的获选参与者。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"a3893e2538b44a4c9453f52433cb6ed2","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02005"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664897466","title":"石四药集团(02005)：受托人根据限制性股份奖励计划购买合共120万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2664897466","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2664897466?lang=zh_cn&edition=full","pubTime":"2026-09-02 16:58","pubTimestamp":1788339493,"startTime":"0","endTime":"0","summary":"智通财经APP讯，石四药集团(02005)发布公告，于2026年9月2日，由公司内部资源拨付，计划受托人根据计划的条款及条件在公开市场上购买合共120万股公司股份，并以信托方式为获选参与者持有该等股份。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1490939.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU2460026573.USD","02005","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1162929738","title":"石四药集团8月股份变动月报表，股本维持不变","url":"https://stock-news.laohu8.com/highlight/detail?id=1162929738","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1162929738?lang=zh_cn&edition=full","pubTime":"2026-09-01 17:12","pubTimestamp":1788253972,"startTime":"0","endTime":"0","summary":"石四药集团有限公司于2026年9月1日发布截至2026年8月31日的证券变动月报表。公告显示，公司法定及注册股本维持在10,000,000,000股，股份面值每股0.02港元，注册股本总额2亿港元，较上月无变化。报告期内未出现新增发行、购回或注销股份情况。公司确认其已满足香港联交所主板上市规则关于公众持股量的相关要求。本次公告由公司执行董事兼公司秘书周兴扬签署，石四药集团表示将继续严格遵循香港联交所《上市规则》及相关法律法规。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02005"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1190494903","title":"石四药集团（02005）限制性股份奖励计划下公开市场回购100万股","url":"https://stock-news.laohu8.com/highlight/detail?id=1190494903","media":"公告速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1190494903?lang=zh_cn&edition=full","pubTime":"2026-09-01 17:11","pubTimestamp":1788253912,"startTime":"0","endTime":"0","summary":"石四药集团（02005）9月1日晚间发布自愿公告，公司限制性股份奖励计划受托人已于2026年9月1日通过公开市场合计购入1,000,000股公司股份，所涉资金由公司内部资源拨付。此次回购均价约为2.7306港元/股，支付总对价约273.06万元。\n本次所购股份占公司当前已发行股份总数的约0.034%。交易完成后，受托人持股数量增至14,180,000股，占公司当前已发行股份总数的约0.480%。\n石四药集团于2018年12月27日采纳限制性股份奖励计划。董事局表示，将根据计划条款不时审阅并酌情决定向获选参与者授予的股份数量。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02005"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664832779","title":"石四药集团(02005.HK)：受托人根据限制性股份奖励计划购买合共100万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2664832779","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2664832779?lang=zh_cn&edition=full","pubTime":"2026-09-01 17:06","pubTimestamp":1788253616,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1191","02005","LU2460026573.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663075717","title":"石四药集团(02005)：受托人根据限制性股份奖励计划购买合共90万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2663075717","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2663075717?lang=zh_cn&edition=full","pubTime":"2026-08-31 16:56","pubTimestamp":1788166606,"startTime":"0","endTime":"0","summary":"智通财经APP讯，石四药集团(02005)发布公告，于2026年8月31日，由本公司内部资源拨付，计划受托人根据限制性股份奖励计划的条款及条件在公开市场上购买合共90万股本公司股份，并以信托方式为获选参与者持有该等股份。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1489439.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU2460026573.USD","BK1191","02005"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662882037","title":"港股公告掘金 | 蜜雪集团上半年实现收入约152.16亿元 同比增长2.3% 全球门店网络持续扩容","url":"https://stock-news.laohu8.com/highlight/detail?id=2662882037","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662882037?lang=zh_cn&edition=full","pubTime":"2026-08-28 09:05","pubTimestamp":1787879123,"startTime":"0","endTime":"0","summary":"重大事项：和黄医药(00013)：爱领达(凡瑞格拉替尼)获中国国家药监局批准用于治疗FGFR2融合/重排的肝内胆管癌患者映恩生物-B(09606)与Genentech订立全球研发合作及许可协议 以基于公司DUPAC新型有效载荷平台开发下一代ADC石四药集团(02005)已取得国家药监局有关钆布醇注射液(7.5ml：4.5354g)的药品生产注册批件固生堂(02273)：收购YC TCM (TAMA","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1487692.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02005","BK1219","BK1588","VXUS","LU2460026573.USD","BK1191","BK1587","BK1161","00013","HK0000500386.USD","KCAI","09606","02097","BK4585","HK0000252152.HKD","BK1233","BK4588","HK0000252160.HKD","LU2543165471.USD","02273","BK1616"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662706077","title":"石四药集团(02005)已取得国家药监局有关钆布醇注射液(7.5ml：4.5354g)的药品生产注册批件","url":"https://stock-news.laohu8.com/highlight/detail?id=2662706077","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662706077?lang=zh_cn&edition=full","pubTime":"2026-08-27 18:55","pubTimestamp":1787828138,"startTime":"0","endTime":"0","summary":"智通财经APP讯，石四药集团 发布公告，集团已取得中国国家药监局有关钆布醇注射液的药品生产注册批件，属于化学药品第4类，视同通过一致性评价。集团已取得国家药监局有关注射用吲哚菁绿，属于化学药品第3类，视同通过一致性评价。集团的吲哚菁绿原料药已获国家药监局批准登记成为在上市制剂使用的原料药。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1487173.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU2460026573.USD","BK1191","02005"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1164453410","title":"石四药集团获批两款诊断用注射剂　完善影像与重症医疗产品布局","url":"https://stock-news.laohu8.com/highlight/detail?id=1164453410","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1164453410?lang=zh_cn&edition=full","pubTime":"2026-08-27 18:52","pubTimestamp":1787827927,"startTime":"0","endTime":"0","summary":"2026年8月27日，石四药集团有限公司发布自愿公告称，公司已取得中国国家药品监督管理局就两款诊断用注射剂的生产注册批件。此前，集团的釓布醇原料药已于2026年7月21日获批登记为上市制剂用原料药。本次粉针剂获批后，将进一步完善集团在围手术期及ICU重症科室的产品布局。石四药集团表示，两款产品的先后获批将有助于拓展医学影像及重症医疗市场，并与现有制剂形成业务协同。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02005"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662376744","title":"港股异动 | 石四药集团(02005.HK)一度涨超5% 上半年纯利同比增近13% 输液产销量实现逆势增长","url":"https://stock-news.laohu8.com/highlight/detail?id=2662376744","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662376744?lang=zh_cn&edition=full","pubTime":"2026-08-26 13:45","pubTimestamp":1787723157,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["02005","LU2460026573.USD","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662622497","title":"石四药集团(02005.HK)上半年归母净利润增长约13%至3.2亿港元  中期息0.055港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2662622497","media":"中金财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662622497?lang=zh_cn&edition=full","pubTime":"2026-08-26 12:47","pubTimestamp":1787719622,"startTime":"0","endTime":"0","summary":"格隆汇8月26日丨石四药集团公布中期业绩，截至2026年6月30日止六个月，实现销售收入以人民币计约20.75亿元，同比增长约5.0%。以港元计，今年上半年销售收入约23.61亿港元，同比增长约9.9%，实现归母净利润约3.20亿港元，同比增长约13.0%。董事局议决于2026年9月24日向于2026年9月11日名列公司股东名册的股东派发中期息0.055港元╱股，同比增加10%。　　2026年上半年，医用材料产品的收益为集团贡献1.18亿港元，较去年同期增加16.8%，主要由新产品销售贡献。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushizhibo/20260826/32347746.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["EWH","02005"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662764020","title":"石四药集团(02005)将于9月24日派发中期股息每股0.055港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2662764020","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662764020?lang=zh_cn&edition=full","pubTime":"2026-08-26 12:27","pubTimestamp":1787718454,"startTime":"0","endTime":"0","summary":"智通财经APP讯，石四药集团(02005)发布公告，该公司将于2026年9月24日派发截至2026年6月30日止6个月的中期股息每股0.055港元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1485819.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["EWH","BK4588","VIG","BK4585","02005","LU2460026573.USD","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1185147546","title":"石四药集团(02005)2026年上半年净利增13%至3.20亿港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1185147546","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1185147546?lang=zh_cn&edition=full","pubTime":"2026-08-26 12:06","pubTimestamp":1787717194,"startTime":"0","endTime":"0","summary":"石四药集团有限公司8月26日披露截至2026年6月30日止六个月未经审核的中期业绩。期内，公司实现收益23.6058亿港元，同比增长9.9%；毛利9.7242亿港元，毛利率41.2%，较上年同期的41.5%下降0.3个百分点。归属于股东的溢利3.2032亿港元，同比增长13.0%；基本及摊薄每股盈利0.1107港元，去年同期为0.0962港元。董事会宣布派发中期股息每股0.055港元，较去年同期的0.050港元增加10.0%，股息将在2026年9月24日派付，股权登记日为9月11日。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02005"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1158101257","title":"石四药集团（02005）宣布派发2026财年中期每股0.055港元股息","url":"https://stock-news.laohu8.com/highlight/detail?id=1158101257","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1158101257?lang=zh_cn&edition=full","pubTime":"2026-08-26 12:06","pubTimestamp":1787717168,"startTime":"0","endTime":"0","summary":"石四药集团有限公司8月26日公告，截至2026年6月30日止六个月，公司将派发中期股息每股0.055港元，股息性质为普通股息，涉及2026年12月31日止财政年度。本次股息的除净日为2026年9月10日；股东如欲获派股息，须于2026年9月11日16时30分前将股份过户文件递交香港中央证券登记有限公司。截至公告日，石四药集团董事会成员包括执行董事曲继广、苏学军、孟国、周兴扬及曲婉蓉；非执行董事刘文军；独立非执行董事王亦兵、周国伟及姜广策。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02005"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1160423914","title":"石四药集团：2026年下半年将聚焦强化运营与稳定预期","url":"https://stock-news.laohu8.com/highlight/detail?id=1160423914","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1160423914?lang=zh_cn&edition=full","pubTime":"2026-08-26 12:03","pubTimestamp":1787717020,"startTime":"0","endTime":"0","summary":"石四药集团近日释放信号，表明其2026年下半年战略重心将落脚于巩固业务运营、稳定市场预期之上。这家药企正以稳健姿态应对行业变局。展望未来数月，公司明确表示将以“强运营、稳预期”为双主线，力求在复杂环境中保持定力。换言之，面对医药行业持续演进的竞争格局与政策环境，石四药集团选择了一条“内功外修”并举的路径。在预期管理愈发重要的当下，石四药集团此举意在为股价表现与估值体系提供更为坚实的支撑。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02005","BK1191","LU2460026573.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1186487815","title":"石四药集团获批奥扎格雷钠注射液生产注册 全面覆盖剂型","url":"https://stock-news.laohu8.com/highlight/detail?id=1186487815","media":"公告速递","labels":["productRelease","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1186487815?lang=zh_cn&edition=full","pubTime":"2026-08-25 17:03","pubTimestamp":1787648598,"startTime":"0","endTime":"0","summary":"2026年8月25日，石四药集团发布自愿公告称，公司已取得中国国家药品监督管理局核发的奥扎格雷钠注射液的药品生产注册批件，产品归属化学药品第3类，视同通过一致性评价。公告披露，石四药集团此前已有奥扎格雷钠氯化钠注射液两个大输液规格获批上市。奥扎格雷钠注射液主要适用于急性血栓性脑梗死及伴随运动障碍的治疗。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02005"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1106032901","title":"石四药集团（02005）获批维生素K1注射液生产注册　完善注射剂产品布局","url":"https://stock-news.laohu8.com/highlight/detail?id=1106032901","media":"公告速递","labels":["productRelease","SGX"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1106032901?lang=zh_cn&edition=full","pubTime":"2026-08-20 12:16","pubTimestamp":1787199383,"startTime":"0","endTime":"0","summary":"石四药集团有限公司8月20日公告称，已获中国国家药品监督管理局核发维生素K1注射液的药品生产注册批件。该产品归属化学药品第3类，视同通过一致性评价。公告指出，维生素K1注射液主要用于治疗维生素K缺乏性出血，并可用于无法通过营养补充方式获得维生素K的预防用药。作为临床基础用药，该产品在出血预防及急救领域应用广泛，市场需求规模较大。石四药集团表示，本次产品获批将进一步丰富公司注射剂产品组合。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02005"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660340857","title":"石四药集团(02005)取得有关维生素K1注射液(1ml:10mg)的药品生产注册批件","url":"https://stock-news.laohu8.com/highlight/detail?id=2660340857","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2660340857?lang=zh_cn&edition=full","pubTime":"2026-08-20 12:05","pubTimestamp":1787198746,"startTime":"0","endTime":"0","summary":"智通财经APP讯，石四药集团(02005)发布公告，集团已取得中国国家药品监督管理局有关维生素K1注射液(1ml:10mg)的药品生产注册批件，属于化学药品第3类，视同通过一致性评价。维生素K1注射液主要用于治疗维生素K缺乏性出血，和预防无法通过营养补充的维生素K缺乏症。维生素K1注射液是临床基础用药，广泛用于出血预防及急救，市场规模庞大。此产品的获批，丰富了集团的注射剂产品组合。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1482454.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU2460026573.USD","BK1191","02005"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.ssygroup.com.hk","stockEarnings":[{"period":"1week","weight":0.0321},{"period":"1month","weight":0.1143},{"period":"3month","weight":0.1818},{"period":"6month","weight":0.1017},{"period":"1year","weight":-0.0137},{"period":"ytd","weight":-0.0229}],"compareEarnings":[{"period":"1week","weight":-0.0133},{"period":"1month","weight":-0.0268},{"period":"3month","weight":0.0023},{"period":"6month","weight":-0.0173},{"period":"1year","weight":-0.0073},{"period":"ytd","weight":-0.0125}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"石四药集团有限公司,前称为利君国际医药（控股）有限公司，是一家主要从事研究、开发、制造及向医院及分销商销售药物产品的投资控股公司。公司的产品主要包括静脉输液的成药、原料药及医用材料。该公司的产品主要包括非聚氯乙烯软袋输液、聚丙烯塑瓶输液和玻璃瓶输液。该公司的产品还包括盐酸倍他司汀、盐酸氨溴索、盐酸罗哌卡因和多索茶碱以及原料药，包括咖啡因、茶碱、氨茶碱、甲硝唑和硝苯地平。","yearOnYearQuotes":[{"month":1,"riseRate":0.52381,"avgChangeRate":0.008158},{"month":2,"riseRate":0.52381,"avgChangeRate":0.020535},{"month":3,"riseRate":0.666667,"avgChangeRate":0.079315},{"month":4,"riseRate":0.47619,"avgChangeRate":0.030939},{"month":5,"riseRate":0.47619,"avgChangeRate":0.010534},{"month":6,"riseRate":0.47619,"avgChangeRate":0.060362},{"month":7,"riseRate":0.380952,"avgChangeRate":-0.020567},{"month":8,"riseRate":0.380952,"avgChangeRate":-0.010373},{"month":9,"riseRate":0.333333,"avgChangeRate":-0.044171},{"month":10,"riseRate":0.45,"avgChangeRate":-0.001891},{"month":11,"riseRate":0.65,"avgChangeRate":0.086083},{"month":12,"riseRate":0.5,"avgChangeRate":-0.009107}],"exchange":"SEHK","name":"石四药集团","nameEN":"SSY GROUP"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"石四药集团(02005)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供石四药集团(02005)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"石四药集团,02005,石四药集团股票,石四药集团股票老虎,石四药集团股票老虎国际,石四药集团行情,石四药集团股票行情,石四药集团股价,石四药集团股市,石四药集团股票价格,石四药集团股票交易,石四药集团股票购买,石四药集团股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"石四药集团(02005)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供石四药集团(02005)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}